Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Cell death & disease - 15 Jul 2021

Ceder Sophia, Eriksson Sofi E, Liang Ying Yu, Cheteh Emarndeena H, Zhang Si Min, Fujihara Kenji M, Bianchi Julie, Bykov Vladimir J N, Abrahmsen Lars, Clemons Nicholas J, Nordlund Pär, Rudd Sean G, Wiman Klas G

Abstract excerpt

Asparaginase depletes extracellular asparagine in the blood and is an important treatment for acute lymphoblastic leukemia (ALL) due to asparagine auxotrophy of ALL blasts. Unfortunately, resistance occurs and has been linked to expression of the enzyme asparagine synthetase (ASNS), which generates asparagine from intracellular sources. Although TP53 is the most frequently mutated gene in cancer overall, TP53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Asparaginase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Cell Proliferation

Share to Drug Resistance, Neoplasm

Share to Drug Synergism

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 34267184
DOI: 10.1038/s41419-021-03988-y
PMCID: PMC8282662

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.PMID 34267184Read ↗

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

Asparagine Synthetase ChemotherapySemantic proximity Read ↗

Mutations in Subunit Interface and B-cell Epitopes Improve Antileukemic Activities of Escherichia coli Asparaginase-IISemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsSemantic proximity Read ↗

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapySemantic proximity Read ↗

Update on the Use of L-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277Semantic proximity Read ↗

Therapeutic Assessment of Targeting ASNS Combined with l -Asparaginase Treatment in Solid Tumors and Investigation of Resistance MechanismsSemantic proximity Read ↗

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277Semantic proximity Read ↗

Therapeutic assessment of targeting ASNS combined with L-Asparaginase treatment in solid tumors and investigation of resistance mechanismsSemantic proximity Read ↗

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.